UA74871C2 - A process for the preparation of imidazole compounds - Google Patents
A process for the preparation of imidazole compounds Download PDFInfo
- Publication number
- UA74871C2 UA74871C2 UA2003087776A UA2003087776A UA74871C2 UA 74871 C2 UA74871 C2 UA 74871C2 UA 2003087776 A UA2003087776 A UA 2003087776A UA 2003087776 A UA2003087776 A UA 2003087776A UA 74871 C2 UA74871 C2 UA 74871C2
- Authority
- UA
- Ukraine
- Prior art keywords
- compound
- methyl
- chlorophenyl
- temperature
- added
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract description 16
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 230000008569 process Effects 0.000 title abstract description 4
- 150000002460 imidazoles Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 abstract description 39
- -1 silyl halide Chemical class 0.000 abstract description 17
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 abstract description 5
- WOYOASASOHZEDR-UHFFFAOYSA-N 4-(3-chlorophenyl)-6-[(4-chlorophenyl)-hydroxy-(3-methylimidazol-4-yl)methyl]-1-methylquinolin-2-one Chemical compound CN1C=NC=C1C(O)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 WOYOASASOHZEDR-UHFFFAOYSA-N 0.000 abstract 1
- IDKYCLCDTGIFBA-UHFFFAOYSA-N 6-(4-chlorobenzoyl)-4-(3-chlorophenyl)-1-methylquinolin-2-one Chemical compound C=1C(=O)N(C)C2=CC=C(C(=O)C=3C=CC(Cl)=CC=3)C=C2C=1C1=CC=CC(Cl)=C1 IDKYCLCDTGIFBA-UHFFFAOYSA-N 0.000 abstract 1
- 239000011541 reaction mixture Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- DCFKHNIGBAHNSS-UHFFFAOYSA-N chloro(triethyl)silane Chemical compound CC[Si](Cl)(CC)CC DCFKHNIGBAHNSS-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 125000000068 chlorophenyl group Chemical group 0.000 description 4
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 102000043276 Oncogene Human genes 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 3
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- KOPOQZFJUQMUML-UHFFFAOYSA-N chlorosilane Chemical compound Cl[SiH3] KOPOQZFJUQMUML-UHFFFAOYSA-N 0.000 description 2
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- CETVQRFGPOGIQJ-UHFFFAOYSA-N lithium;hexane Chemical compound [Li+].CCCCC[CH2-] CETVQRFGPOGIQJ-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 150000003892 tartrate salts Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- 150000005208 1,4-dihydroxybenzenes Chemical class 0.000 description 1
- QYEMNJMSULGQRD-UHFFFAOYSA-N 1-methyl-2-quinolone Chemical compound C1=CC=C2C=CC(=O)N(C)C2=C1 QYEMNJMSULGQRD-UHFFFAOYSA-N 0.000 description 1
- YONLFQNRGZXBBF-UHFFFAOYSA-N 2,3-dibenzoyloxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)OC(C(O)=O)C(C(=O)O)OC(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-UHFFFAOYSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000007317 Farnesyltranstransferase Human genes 0.000 description 1
- 108010007508 Farnesyltranstransferase Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000013404 Geranyltranstransferase Human genes 0.000 description 1
- 108010026318 Geranyltranstransferase Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 208000010642 Porphyrias Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- TZPZCTBZJKZFGY-UHFFFAOYSA-N chloro-tris(2-methylpropyl)silane Chemical compound CC(C)C[Si](Cl)(CC(C)C)CC(C)C TZPZCTBZJKZFGY-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- IWYZTXQESXGICT-UHFFFAOYSA-N dibenzoyl butanediperoxoate Chemical compound C(CCC(=O)OOC(C1=CC=CC=C1)=O)(=O)OOC(C1=CC=CC=C1)=O IWYZTXQESXGICT-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006126 farnesylation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000002737 fuel gas Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical group CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epoxy Resins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01200928 | 2001-03-12 | ||
| PCT/EP2002/002459 WO2002072574A1 (fr) | 2001-03-12 | 2002-03-05 | Procede de preparation de composes imidazole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA74871C2 true UA74871C2 (en) | 2006-02-15 |
Family
ID=8180004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2003087776A UA74871C2 (en) | 2001-03-12 | 2002-05-03 | A process for the preparation of imidazole compounds |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US6844439B2 (fr) |
| EP (1) | EP1373255B1 (fr) |
| JP (1) | JP4257698B2 (fr) |
| KR (1) | KR100849042B1 (fr) |
| CN (1) | CN1246318C (fr) |
| AR (1) | AR035944A1 (fr) |
| AT (1) | ATE287882T1 (fr) |
| AU (1) | AU2002253101B2 (fr) |
| BR (1) | BRPI0208075B8 (fr) |
| CA (1) | CA2438421C (fr) |
| CZ (1) | CZ300622B6 (fr) |
| DE (1) | DE60202755T2 (fr) |
| DK (1) | DK1373255T3 (fr) |
| EA (1) | EA006770B1 (fr) |
| EE (1) | EE05247B1 (fr) |
| ES (1) | ES2236505T3 (fr) |
| HK (1) | HK1063315A1 (fr) |
| HR (1) | HRP20030695B1 (fr) |
| HU (1) | HU230282B1 (fr) |
| IL (2) | IL157839A0 (fr) |
| MX (1) | MXPA03008205A (fr) |
| MY (1) | MY124838A (fr) |
| NO (1) | NO324954B1 (fr) |
| NZ (1) | NZ528620A (fr) |
| PL (1) | PL208238B1 (fr) |
| PT (1) | PT1373255E (fr) |
| SI (1) | SI1373255T1 (fr) |
| SK (1) | SK287807B6 (fr) |
| TW (1) | TWI249532B (fr) |
| UA (1) | UA74871C2 (fr) |
| WO (1) | WO2002072574A1 (fr) |
| ZA (1) | ZA200307117B (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002072090A1 (fr) | 2001-03-12 | 2002-09-19 | Avanir Pharmaceuticals | Composes de benzimidazole modulateurs de l'ige et inhibiteurs de la proliferation cellulaire |
| TWI276631B (en) | 2002-09-12 | 2007-03-21 | Avanir Pharmaceuticals | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
| WO2004024655A2 (en) | 2002-09-12 | 2004-03-25 | Avanir Pharmaceuticals | Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation |
| CA2559221A1 (fr) * | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Procedes pour le traitement de synucleinopathies |
| JP4917022B2 (ja) * | 2004-05-03 | 2012-04-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ６−ブロモ−４−（３−クロロフェニル）−２−メトキシ−キノリンを用いるジアステレオ選択的合成方法 |
| ES2308486T3 (es) | 2004-05-03 | 2008-12-01 | Janssen Pharmaceutica Nv | Proceso de sintesis diastereoselectiva para la preparacion de compuestos de imidazol. |
| ES2308500T3 (es) * | 2004-05-03 | 2008-12-01 | Janssen Pharmaceutica Nv | Adicion diastereoselectiva de n-metilimidazol en sulfiniminas. |
| WO2007075923A2 (fr) | 2005-12-23 | 2007-07-05 | Link Medicine Corporation | Traitement de formes de synucleinopathie |
| US8232402B2 (en) * | 2008-03-12 | 2012-07-31 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
| KR101044430B1 (ko) * | 2009-09-25 | 2011-06-27 | 듀오백코리아 주식회사 | 요추받이를 포함하는 의자의 등 지지 장치 |
| KR101107900B1 (ko) * | 2009-10-21 | 2012-01-25 | 성용기업 주식회사 | 의자용 허리지지장치 |
| ES2901506T3 (es) | 2015-08-17 | 2022-03-22 | Kura Oncology Inc | Métodos para tratar pacientes con cáncer con inhibidores de la farnesiltransferasa |
| PT3534885T (pt) | 2016-11-03 | 2021-04-13 | Kura Oncology Inc | Inibidores de farnesiltransferase para usar em métodos de tratamento do cancro |
| CN110234639A (zh) | 2016-12-08 | 2019-09-13 | 杭州领业医药科技有限公司 | 替吡法尼的晶型及其制备方法及药物组合物 |
| CA3100706A1 (fr) * | 2018-05-18 | 2019-11-21 | Kura Oncology, Inc. | Synthese de tipifarnib |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW349948B (en) | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
| AU711142B2 (en) * | 1995-12-08 | 1999-10-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibiting (imidazol-5-YL)methyl-2-quinolinone derivatives |
| TW591030B (en) * | 1997-03-10 | 2004-06-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles |
| NZ336233A (en) * | 1997-04-25 | 2001-01-26 | Janssen Pharmaceutica Nv | Phenyl substituted quinazolines on 4-position and 2-quinazolinone moiety bearing a carbon or nitrogen-linked imidazolyl moiety |
| CA2341739C (fr) | 1998-08-27 | 2005-07-12 | Pfizer Products Inc. | Derives de quinolin-2-one utiles en tant qu'agents anticancereux |
| ES2259237T3 (es) | 1998-08-27 | 2006-09-16 | Pfizer Products Inc. | Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos. |
-
2002
- 2002-03-05 PL PL363263A patent/PL208238B1/pl unknown
- 2002-03-05 CA CA2438421A patent/CA2438421C/fr not_active Expired - Lifetime
- 2002-03-05 HU HU0303443A patent/HU230282B1/hu unknown
- 2002-03-05 AT AT02722184T patent/ATE287882T1/de active
- 2002-03-05 EE EEP200300442A patent/EE05247B1/xx unknown
- 2002-03-05 EA EA200300998A patent/EA006770B1/ru not_active IP Right Cessation
- 2002-03-05 EP EP02722184A patent/EP1373255B1/fr not_active Expired - Lifetime
- 2002-03-05 DK DK02722184T patent/DK1373255T3/da active
- 2002-03-05 KR KR1020037010091A patent/KR100849042B1/ko active IP Right Grant
- 2002-03-05 US US10/471,215 patent/US6844439B2/en not_active Expired - Lifetime
- 2002-03-05 MX MXPA03008205A patent/MXPA03008205A/es active IP Right Grant
- 2002-03-05 CN CNB02806335XA patent/CN1246318C/zh not_active Expired - Lifetime
- 2002-03-05 JP JP2002571490A patent/JP4257698B2/ja not_active Expired - Lifetime
- 2002-03-05 AU AU2002253101A patent/AU2002253101B2/en not_active Expired
- 2002-03-05 CZ CZ20032704A patent/CZ300622B6/cs not_active IP Right Cessation
- 2002-03-05 BR BRPI0208075-3 patent/BRPI0208075B8/pt not_active IP Right Cessation
- 2002-03-05 WO PCT/EP2002/002459 patent/WO2002072574A1/fr active IP Right Grant
- 2002-03-05 ES ES02722184T patent/ES2236505T3/es not_active Expired - Lifetime
- 2002-03-05 IL IL15783902A patent/IL157839A0/xx unknown
- 2002-03-05 PT PT02722184T patent/PT1373255E/pt unknown
- 2002-03-05 SK SK1246-2003A patent/SK287807B6/sk unknown
- 2002-03-05 DE DE60202755T patent/DE60202755T2/de not_active Expired - Lifetime
- 2002-03-05 SI SI200230100T patent/SI1373255T1/xx unknown
- 2002-03-05 NZ NZ528620A patent/NZ528620A/en not_active IP Right Cessation
- 2002-03-11 AR ARP020100873A patent/AR035944A1/es active IP Right Grant
- 2002-03-11 MY MYPI20020866A patent/MY124838A/en unknown
- 2002-03-11 TW TW091104444A patent/TWI249532B/zh not_active IP Right Cessation
- 2002-05-03 UA UA2003087776A patent/UA74871C2/uk unknown
-
2003
- 2003-09-01 HR HR20030695A patent/HRP20030695B1/xx not_active IP Right Cessation
- 2003-09-10 IL IL157839A patent/IL157839A/en unknown
- 2003-09-10 NO NO20034003A patent/NO324954B1/no not_active IP Right Cessation
- 2003-09-11 ZA ZA200307117A patent/ZA200307117B/en unknown
-
2004
- 2004-08-12 HK HK04106065A patent/HK1063315A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA74871C2 (en) | A process for the preparation of imidazole compounds | |
| US10870626B2 (en) | Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds | |
| WO2010140168A1 (fr) | Procédé amélioré pour la préparation de témozolomide | |
| AU2002253101A1 (en) | Process for the preparation of imidazole compounds | |
| US6706890B2 (en) | Method for producing oxindoles | |
| RU2320655C2 (ru) | УЛУЧШЕННЫЙ СПОСОБ ПОЛУЧЕНИЯ α-ПОЛИМОРФНОГО БРОМГИДРАТА ЭЛЕТРИПТАНА | |
| EP1274702A1 (fr) | Procede de synthese d'un derive connu du tetrazol | |
| US20050245750A1 (en) | Process for preparing 1,3-benzodioxole-2-spirocycloalkane derivative | |
| CN112979552A (zh) | 一种高纯度盐酸右美托咪定的制备方法 | |
| AU2005238222B2 (en) | Diastereoselective synthesis process with 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline | |
| FR2710066A1 (fr) | Dérivés de 1-[2-amino-5-[1-(triphénylméthyl-1H-imidazol-4-yl]-1-oxopentyl]piperidine, leur préparation et leur utilisation comme intermédiaires de synthèse. | |
| CA2166032A1 (fr) | Derives de 1-oxo-2-(phenylsulfonylamino) pentylpiperidine, leur preparation et leur application en therapeutique | |
| EP2496570B1 (fr) | Procédé pour l'élaboration de 5-(2-amino-pyrimidin-4-yl)-2-aryl-1h-pyrrole-3-carboxamides | |
| CA2131764A1 (fr) | Acides et chlorures d'acides 1,2,3,4-tetrahydroquinoleine-8-sulfoniques, leur preparation et leur utilisation comme in ermediaires de snythese | |
| WO2022218987A1 (fr) | Procédé de préparation de dérivés de n-aryl-formamidine fongicides | |
| CN117858866A (zh) | 用于制备色胺衍生物的方法 | |
| EP2152697A2 (fr) | Procédé de préparation de l'alfuzosine et de ses sels | |
| JPH05345782A (ja) | アデニン誘導体の製造方法 | |
| KR20110083892A (ko) | 탈보호화 반응을 이용한 고혈압 치료용 비페닐테트라졸 화합물의 제조방법 |